Development and Evaluation of Losartan Potassium Floating Matrix Tablet
Abstract
The present study was aimed towards the development of controlled release formulations of Losartan Potassium based on designed to enhance the bioavailability by prolonging its duration in the stomach via the floating dosage forms with controlled release. This study was intended to evaluate the influence of formulation variables like levels of polymer, amount of mannitol concentrations, and coating solution ratios of semi permeable membrane on the drug release from the developed formulations. Thus, there is a strong clinical need and market potential for a dosage form that will deliver Losartan Potassium in a controlled manner to a patient needing this therapy, thereby resulting in a better patient compliance. This study was designed to enhance the bioavailability of drug by prolonging its duration in the stomach via the floating dosage forms with controlled release. Floating matrix tablets of Losartan Potassium were prepared by the direct compression method, using locust bean gum and HPMC K 15M as polymers and Sodium bicarbonate as floating agent. The effect of the nature of polymers was studied by preparing various formulations of tablets. In all these formulations, a constant amount of drug (100 mg) was maintained. The blend was initially characterized for pre-compression and post- compression parameters. Pre-compression characterization was done for angle of repose, bulk density, tapped density, Carr’s index, and Hausner’s ratio. The results of pre-compression characterization were indicated good to excellent flow characteristics. Post-compression characterization includes thickness, hardness, friability, weight variation, drug content, buoyancy lag time, floating time and in-vitro drug release. All the results were satisfactory as per the guideline of pharmacopoeia. The in vitro drug release studies found that formulations LPFT4 showed best sustained release profile in 24 hrs. Among the nine formulations (LPFT1 to LPFT9) prepared formulations LPFT4 was found to be the best formulations in terms of sustained drug release. Drug release kinetics was performed by using various kinetic models such as Zero order, First order, Korsmeyer- Peppas and Higuchi’s equation and followed supercase II transport diffusion kinetic models.
Keywords: Oral drug delivery system, Gastroretentive technology, losartan potassium, floating tablet, matrix tablet
Keywords:
Oral drug delivery system, Gastroretentive technology, losartan potassium, floating tablet, matrix tabletDOI
https://doi.org/10.22270/jddt.v12i3-S.5388References
Fellermann K, Stange EF, "Defensins - innante immunity at the epithelial frontier", European Journal Gastroenterology Hepatology, 2001; 13:771- 5. https://doi.org/10.1097/00042737-200107000-00003
Gewirtz AT, "Intestinal epithelial pathobiology: past, present and future", Best Pract Research Clinical Gastroenterology, 2002, 16, 851-859. https://doi.org/10.1053/bega.2002.0339
Singh BN, Kim KH. In Drug Dlivery: Oral Route. In: Swarbrick J, editor. Encyclopedia of Pharmaceutical Technology. 3rd Edn; New York: Informa Healthcare USA, Inc., USA, 2007, pp 1242- 1244.
Friend DR, "New oral delivery systems for treatment of inflammatory bowel disease", Advanced Drug Delivery Reviews, 2005; 57:247-65. https://doi.org/10.1016/j.addr.2004.08.011
Someshwar K, Chithaluru K, Ramarao T, Kumar KK. Formulation and evaluation of effervescent floating tablets of tizanidine hydrochloride. Acta Pharm. 2011; 61(2):217-226. https://doi.org/10.2478/v10007-011-0015-5
Kotreka UK, Adeyeye MC. Gastroretentive floating drug-delivery systems: a critical review. Crit. Rev. Ther. Drug Carrier Syst. 2011; 28(1):47-99. https://doi.org/10.1615/CritRevTherDrugCarrierSyst.v28.i1.20
Singh BN, Kim KH. Floating drug delivery systems: an approach to oral controlled drug delivery via gastric retention. J. Control. Release 2000; 63(3):235- 259. https://doi.org/10.1016/S0168-3659(99)00204-7
Ali J, Arora S, Ahuja A, Babbar AK, Sharma RK, Khar RK, Baboota S. Formulation and development of hydrodynamically balanced system for metformin: in vitro and in vivo evaluation. Eur. J. Pharm. Biopharm. 2007; 67(1):196-201. https://doi.org/10.1016/j.ejpb.2006.12.015
Published
Abstract Display: 390 
PDF Downloads: 413 PDF Downloads: 21 How to Cite
Issue
Section
Authors who publish with this journal agree to the following terms:
- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0). that allows others to share the work with an acknowledgment of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgment of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).
How to Cite
.